Ruifu Pharmaceutical

Ruifu Pharmaceutical (Ruifu Pharmaceutical Technology (Guangzhou) Co., Ltd.) is a Chinese clinical-stage biotechnology company specializing in the development of innovative small molecule and small nucleic acid (oligonucleotide) drugs. Founded in 2021 and headquartered in Guangzhou, with its R&D center (Nanjing Hongdi Biotechnology) in Nanjing, the company leverages its proprietary carbocyclic nucleoside modification (cLNA) platform to design highly stable and efficient nucleic acid therapeutics. Its lead candidate, RF2011, is a novel antisense oligonucleotide (ASO) targeting chronic hepatitis B virus (HBV) infection, which received IND approval from China's CDE and entered Phase 1 clinical trials in late 2026. Led by industry veteran Dr. Xiaoning Christopher Sheng, Ruifu Pharmaceutical aims to address major unmet medical needs globally.